期刊论文详细信息
Nutrition & Metabolism
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
Kazim Sahin2  Fikrettin Sahin5  Okkes Yilmaz3  Ibrahim H Ozercan6  Mehmet Tuzcu3  Zeynep Tuzcu3  Ertugrul Kilic1  Ulkan Kilic4 
[1] Department of Physiology, Faculty of Medicine, Medipol University, Istanbul, Turkey;Department of Animal Nutrition, Faculty of Veterinary Science, Firat University, Elazig, Turkey;Department of Biology, Faculty of Science, Firat University, Elazig, Turkey;Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Adnan Menderes Bulvarı Vatan Caddesi, Fatih, TR-34093, Istanbul, Turkey;Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey;Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey
关键词: Oxidative stress;    Melatonin;    Nrf2/HO-1 signaling;    Nephrotoxicity;   
Others  :  811351
DOI  :  10.1186/1743-7075-10-7
 received in 2012-08-07, accepted in 2013-01-08,  发布年份 2013
PDF
【 摘 要 】

Background

Cisplatin, one of the most effective and potent anticancer drugs, is used in the treatment of a wide variety of both pediatric and adult malignancies. However, the chemotherapeutic use of cisplatin is limited by its serious side-effects such as nephrotoxicity and ototoxicity. Cisplatin chemotherapy induces a reduction in the antioxidant status, leading to a failure of the antioxidant defense against free-radical damage generated by antitumor drugs. Cisplatin-induced oxidative stress in the kidney was partially prevented by antioxidant treatments using superoxide dismutase, glutathione, selenium and flavonoids. Melatonin and its metabolites possess free-radical scavenging activity and it has been shown that they protect against cisplatin toxicity. However, the mechanism of the protective effects of melatonin against cisplatin-induced nephrotoxicity is still essentially unknown. We therefore designed this study to investigate the underlying mechanism of the protective effect of melatonin against cisplatin-induced renal damage in a rat nephrotoxicity model in vivo.

Methods

Twenty eight 8-week-old male Wistar rats were divided into four groups of control, melatonin treatment (4 mg/kg b.w i.p. for 10 days), cisplatin treatment (7 mg/kg b.w., i.p.) and melatonin and cisplatin combination treatment. Serum urea nitrogen (urea-N) and creatinine levels were measured. Histopathological changes were evaluated. In addition, we analyzed the expression levels of HO-1, Nrf2, NF-κB and AP-1 in Western blot analysis.

Results

Both serum creatinine and urea nitrogen increased significantly following cisplatin administration alone; these values decreased significantly with melatonin co-treatment of cisplatin-treated rats. Histological analysis showed that cisplatin caused damage in the proximal tubular cells in the kidneys of cisplatin-treated rats; these changes were reversed by melatonin co-treatment. Upon Western blot analysis, melatonin treatment increased Nrf2 accumulation in the nuclear fraction, and increased the expression of HO-1 in the cytosolic fraction as compared to the cisplatin-treated rats. Expressions of NF-κB p65 and AP-1 were increased significantly in the kidneys of rats treated with cisplatin compared with the expression in the kidneys from the control, melatonin-only-treated and melatonin co-treated rats.

Conclusion

Our present data suggest that melatonin attenuates cisplatin-induced nephrotoxicity possibly by modulating Nrf2/HO-1 signaling.

【 授权许可】

   
2013 Kilic et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140709063359686.pdf 1393KB PDF download
Figure 2. 206KB Image download
Figure 1. 216KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J: Cisplatin nephrotoxicity. Am J Kidney Dis 1986, 8:356-367.
  • [2]Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992, 10:574-579.
  • [3]Luke DR, Vadiei K, Lopez-Berestein G: Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992, 37(1):1-7.
  • [4]Jamieson ER, Lippard SJ: Structure, recognition, and processing of cisplatin–DNA adducts. Chem Rev 1999, 99:2467-2498.
  • [5]Davis CA, Nick HS, Agarwal A: Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001, 12:2683-2690.
  • [6]Rahman I, Biswas SK, Kirkham PA: Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006, 72:1439-1452.
  • [7]Shimeda Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T, Tanaka K: Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull 2005, 28:1635-1638.
  • [8]Santos NA, Catão CS, Martins NM, Curti C, Bianchi ML, Santos AC: Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007, 81:495-504.
  • [9]Kotins MS, Patel P, Menon SN, Sane RT: Renoprotective effect of Hemidesmus indicus, a herbal drug used in gentamicin-induced renal toxicity. Nephrology 2004, 9:142-147.
  • [10]Rao NK, Nammi S: Antidiabetic and renoprotective effects of the chloroform extract of Terminalia chebula Retz. seeds in treptozotocin-induced diabetic rats. BMC Complement Altern Med 2006, 6:17-22. BioMed Central Full Text
  • [11]Sies H, Masumoto H: Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Adv Pharmacol 1997, 38:229-246.
  • [12]Huang HC, Nguyen T, Pickett CB: Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002, 277:42769-42774.
  • [13]Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA: Nrf2, a multi-organ protector? FASEB J 2005, 19:1061-1066.
  • [14]Motohashi H, O'Connor T, Katsuoka F, Engel JD, Yamamoto M: Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002, 294:1-12.
  • [15]Yates MS, Kensler TW: Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 2007, 28:1331-1342.
  • [16]Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
  • [17]Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2:725-734. 48
  • [18]Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E: When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 2005, 230:104-117.
  • [19]Reiter RJ, Paredes SD, Manchester LC, Tan DX: Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009, 44:175-200.
  • [20]Hardeland R, Tan DX, Reiter RJ: Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009, 47:109-126.
  • [21]Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ: One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007, 42:28-42.
  • [22]Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisetti S: Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007, 52:11-28.
  • [23]Kilic U, Yilmaz B, Ugur M, Yuksel A, Reiter RJ, Hermann DM, Kilic E: Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012, 52:228-235.
  • [24]Jung KH, Hong SW, Zheng HM, Lee DH, Hong SS: Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 2009, 47:173-183.
  • [25]Jung KH, Hong SW, Zheng HM, Lee HS, Lee H, Lee DH, Lee SY, Hong SS: Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res 2010, 48:239-250.
  • [26]Negi G, Kumar A, Sharma SS: Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res 2011, 50:124-131.
  • [27]Anand AH, Bashey B: Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993, 27:1519-1525.
  • [28]Morishima I, Okumura K, Matsui H, Kaneko S, Numaguchi Y, Kawakami K, Makuno S, Hayakawa M, Toki Y, Ito T, Hayakawa T: Zinc accumulation in Adriamycin-induced cardiyomyopathy in rats: Effects of melatonin, a cardiyoprotective agent. J Pineal Res 2004, 26:204-210.
  • [29]Lopez-Gonzales MA, Guerrero JM, Toronteras R, Osuna C, Delgado F: Ototoxicity caused by aminoglucusides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs. J Pineal Res 2000, 28:26-33.
  • [30]Sahin K, Tuzcu M, Sahin N, Ali S, Kucuk O: Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene. Food Chem Toxicol 2010, 48:2670-2674.
  • [31]Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM: Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res 2005, 38:67-71.
  • [32]Ross MH, Reith EJ, Romrell LJ: Histology-A Text and Atlas (ki sp k). Baltimore, MD: Williams and Wilkins; 1989.
  • [33]Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002, 110(6):835-842.
  • [34]Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M: Direct involvement of the receptor-mediated apoptotic pathways in cisplatin induced renal tubular cell death. Kidney Int 2003, 63:72-82.
  • [35]Ali S, Mann DA: Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct 2004, 22:67-79.
  • [36]Surh YJ, Na HK: NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2008, 2:313-317.
  • [37]Prawan A, Kukongviriyapan V, Tassaneeyakul W, Pairojkul C, Bhudhisawasdi V: Association between genetic polymorphisms of CYP1A2, arylamine Nacetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur J Cancer Prev 2005, 14:245-250.
  • [38]Prawan A, Kundu JK, Surh YJ: Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal 2005, 7:1688-1703.
  • [39]Surh YJ, Kundu JK, Na HK: Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008, 74:1526-1539.
  • [40]McNally A, Dalton T, La Ragione RM, Stapleton K, Manning G, Newell DG: Yersinia enterocolitica isolates of differing biotypes from humans and animals are adherent, invasive and persist in macrophages, but differ in cytokine secretion profiles in vitro. J Med Microbiol 2006, 55:1725-1734.
  • [41]Maines MD, Gibbs PE: 30 some years of heme oxygenase: from a “molecular wrecking ball” to a “mesmerizing” trigger of cellular events. Biochem Biophys Res Commun 2005, 338:568-577.
  • [42]Beni SM, Kohen R, Reiter RJ, Tan DX, Shohami E: Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappaB and AP-1. FASEB J 2004, 18(1):149-151.
  • [43]Lee S, Moon SO, Kim W, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Lee SY, Park SK: Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol Dial Transplant 2006, 21:2085-2095.
  • [44]Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, Biswal S: Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116:984-995.
  • [45]Jin W, Wang H, Yan W, Xu L, Wang X, Zhao X, Yang X, Chen G, Ji Y: Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators Inflamm 2008, 72:51-74.
  • [46]Hardeland R, Backhaus C, Fadavi A: Reactions of the NO redox forms NO+, *NO and HNO (protonated NO) with the melatonin metabolite N1-acetyl-5-methoxykynuramine. J Pineal Res 2007, 43:382-388.
  • [47]Reiter RJ, Tan DX, Osuna C, Gitto E: Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000, 7:444-458.
  • [48]Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S, Honma K, Kondo T: Melatonin induces gammaglutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999, 27:838-847.
  • [49]Gitto E, Tan DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, Fulia F, Barberi I: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 2001, 53:1393-1401.
  • [50]Mayo JC, Tan DX, Sainz RM, Lopez-Burillo S, Reiter RJ: Oxidative damage to catalase induced by peroxyl radicals: functional protection by melatonin and other antioxidants. Free Radic Res 2003, 37:543-553. 2009
  • [51]Wang Z, Zhang J, Liu H, Huang H, Wang C, Shen Y, Li D, Jing H: Melatonin, a potent regulator of hemeoxygenase-1, reduces cardiopulmonary bypass-induced renal damage in rats. J Pineal Res 2009, 46:248-254.
  • [52]Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S: Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002, 54:1299-1321.
  • [53]Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS: Preclinical evaluation ofpharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 2006, 41:337-343.
  • [54]Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM: Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004, 37:247-251.
  • [55]Kilic E, Kilic U, Yulug B, Hermann DM, Reiter RJ: Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res 2004, 36:171-176. 16
  • [56]Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM: Tissue-plasminogen activator- induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt. J Pineal Res 2005, 39:151-155.
  • [57]Pei Z, Pang SF, Cheung RT: Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2002, 32:168-172.
  • [58]Sun FY, Lin X, Mao LZ, Ge WH, Zhang LM, Huang YL, Gu J: Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J Pineal Res 2002, 33:48-56.
  • [59]Ortiz GG, Benitez-King GA, Rosales-Corral SA, Pacheco-Moises FP, Velazquez-Brizuela IE: Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropharmacol 2008, 6:203-214.
  • [60]Paulis L, Pechanova O, Zicha J, Krajcirovicova K, Barta A, Pelouch V, Adamcova M, Simko F: Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-l-arginine-methyl ester hypertensive rats. J Hypertens 2009, 27(Suppl. 6):S11-S16.
  • [61]Sener G, Sehirli AO, Altunbas H, Ersoy Y: Melatonin protects against gentamicin-induced nephrotoxicity in rats. J Pineal Res 2002, 32:231-236.
  • [62]Dziegiel P, Suder E, Surowiak P, Jethon Z, Rabczyński J, Januszewska L, Sopel M, Zabel M: Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res 2002, 33:95-100.
  • [63]Nava M, Romero F, Quiroz Parra G, Bonet L, Rodriguez-Iturbe B: Melatonin attenuates acute renal failure and oxidative stress induced by mercury chloride in rats. Am J Physiol Renal Physiol 2000, 279:F910-F918.
  • [64]Hara M, Yoshida M, Nishijima H, Yokosuka M, Iigo M, Ohtani-Kaneko R, Shimada A, Hasegawa T, Akama Y, Hirata K: Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001, 30:129-138.
  • [65]Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S, Galli : Melatonin signaling and cell protection function. FASEB J 2010, 24(10):3603-3624.
  • [66]Veneroso C, Tunon MJ, Gonzalez-Gallego J, Collado PS: Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 2009, 47:184-191.
  • [67]Ozbek E, Ilbey YO, Ozbek M, Simsek A, Cekmen M, Somay A: Melatonin attenuates unilateral ureteral obstruction- induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-κB expression. J Endourol 2009, 23:1165-1173.
  文献评价指标  
  下载次数:4次 浏览次数:4次